Wang, Chia-shi http://orcid.org/0000-0001-6941-0057
Troost, Jonathan P
Wang, Yujie
Greenbaum, Larry A
Gibson, Keisha
Trachtman, Howard
Srivastava, Tarak
Reidy, Kimberly
Kaskel, Frederick
Sethna, Christine B
Meyers, Kevin
Dell, Katherine M
Tran, Cheryl L
Hingorani, Sangeeta
Lemley, Kevin V
Lin, Jen-Jar
Gipson, Debbie S
Funding for this research was provided by:
National Institutes of Health (U54‐DK‐083912)
Nephcure Foundation
Halpin Foundation
University of Michigan
National Institute of Diabetes and Digestive and Kidney Diseases (K23DK118189)
Article History
Received: 12 March 2021
Revised: 17 May 2021
Accepted: 9 June 2021
First Online: 18 November 2021
Declarations
:
: Institutional review board (IRB) approval for this study was obtained via the single IRB of record at the University of Michigan.
: Consent for study participation was obtained at NEPTUNE enrollment from the legal guardians of the minor participants. Assent was obtained where applicable according to single and local IRB guidelines.
: Tarak Srivastava has received research funding from Bristol-Myers-Squibb, Retrophin, Mallinckrodt, and Alexion, and has consulted for Alnylam. Larry A. Greenbaum receives research support from Reata Pharmaceuticals and Vertex. He also serves as a consultant for Travere. Howard Trachtman has consultancy agreements through NYU Grossman School of Medicine with Travere Therapeurtics and Goldfinch Bio. He is a consultant to Otsuka and Chemocentryx as member of study data monitoring committees. Debbie S Gipson receives research support from Goldfinch Bio, Novartis, Travere, and Reata. She is a scientific advisor through the University of Michigan with Vertex and AstraZeneca. Kimberly Reidy is a site investigator for Advicienne- and Travere-sponsored clinical trials. Katherine Dell is a site investigator for Travere and AMGEN- sponsored clinical trials and has a consultancy agreement with Sanofi Genzyme.